Loading
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Latest filing published 24 Aug 2023 for MyMD Pharmaceuticals, Inc., €154k.
Filing timeline
BuySalePaul Rivard
Insider track record
Disclosed buys
4
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Paul Rivard: trading record in brief
This profile gathers the share dealings of Paul Rivard in Q/c Technologies, Inc., where the filings describe the role as chief executive. We count 4 filings; the first trade dates from 23 November 2021 and the latest from 24 August 2023.
The open-market record is one-sided, with 4 purchases worth €275k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2023: 2 purchases and no sales on the market.
In size, the median ticket on the buying side is €53k. No cluster: in 4 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 24 August 2023, reports an open-market purchase of €154k in Q/c Technologies, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Paul Rivard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
150,000 shares@ US$1.1143.4% of flowCommon stockSEC:0001493152-23-030111:0
Canonical exit: 22 Nov 2023 (T+90)
25,000 shares@ US$1.12327.3% of flowCommon stockSEC:0001493152-23-029445:0
Canonical exit: 15 Nov 2023 (T+90)
10,000 shares@ US$1.534.1% of flowCommon stockSEC:0001493152-22-034969:0
Canonical exit: 8 Mar 2023 (T+90)
15,000 shares@ US$6.0329.3% of flowCommon stockSEC:0001493152-21-029774:0
Canonical exit: 21 Feb 2022 (T+90)
4 of 4 declarations
